AstraZeneca

Ascentage Pharma's olverembatinib, a third-generation BCR-ABL inhibitor, has its new indication for adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs) included in the China 2024 National Reimbursement Drug List (NRDL), effective January 1, 2025.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology holding the largest revenue share. Key players include IQVIA, Fortrea Inc., PAREXEL, and Thermo Fisher Scientific.

A trial found that a single high-dose injection of benralizumab, targeting eosinophils to reduce lung inflammation, was more effective than steroid tablets in treating severe asthma and COPD attacks, cutting the need for further treatment by 30%.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology leading by indication. Key players include IQVIA, Fortrea Inc., and PAREXEL International Corporation.

AstraZeneca's Phase III CAPItello-281 trial showed Truqap (capivasertib) + abiraterone + ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer. Early OS signs also suggest benefit, with ongoing trial for further assessment. Truqap + Faslodex was approved in the EU for ER-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations.

Roche's Phase 3 trial SKYSCRAPER-01 showed tiragolumab did not improve survival in advanced lung cancer, failing to meet primary goals. Despite earlier promising data, final analysis indicated no sustained benefit. Roche will review tiragolumab's development, while other companies continue TIGIT drug research, hoping for breakthroughs.

SkyQuest projects the global personalized medicines market to reach USD 1352.81 Billion by 2031, with a CAGR of 11.40% driven by innovative therapies, partnerships, and advancements in genomics and AI-powered diagnostics. North America leads due to favorable regulatory frameworks and high R&D spending.

AstraZeneca terminated OUD drug AZD4041 development due to drug-drug interaction with antifungal itraconazole. Despite challenges, non-opioid medications are under development, but efficacy data is lacking. Opioid agonist therapies are expected to drive $1.75 billion in sales by 2033, reflecting patient preference and lack of alternatives. KOLs view OUD as a relapsing-remitting disorder, naturally inclined towards opioid use, making non-opioid treatments only adjunctive. The market lacks effective non-opioid therapies, but a strong profile could disrupt the OUD market.

Study finds states with higher economic vulnerability and minoritized populations have fewer gynecological cancer trials per 100,000 persons, highlighting the need for efforts to address these disparities.